ipamorelin clinical trial safety efficacy and of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance | Sports Medicine Tesamorelin & Ipamorelin Blend For
Description
Studies suggest it may raise GH levels by 2001000% and increase mean plasma IGF-1 concentrations by 1.53 fold, with effects persisting for 68 days under experimental conditions
This is the reason why the results of the first trial in patients with uterine myomas treated with a GnRHAT (called Nal-Glu) appeared only in 1993
It inhibited serotonin- and epinephrine-induced platelet aggregation in vitro and ex vivo [125,126]
doi: 10.1016/S0928-4257(99)00123-0
